These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

43 related articles for article (PubMed ID: 10929588)

  • 1. Radioimmunotherapy effective first-line treatment for non-Hodgkin's lymphoma.
    Oncology (Williston Park); 2000 Jul; 14(7):1009, 1039. PubMed ID: 10929588
    [No Abstract]   [Full Text] [Related]  

  • 2. Radioimmunotherapy in the treatment of non-Hodgkin's lymphoma.
    Whelton S
    Nurse Pract; 2007 Dec; 32(12):35-8. PubMed ID: 18043410
    [No Abstract]   [Full Text] [Related]  

  • 3. Dosimetry and radioimmunotherapy of non-Hodgkin's lymphoma.
    Postema EJ
    J Nucl Med; 2004 Dec; 45(12):2126-7; author reply 2127. PubMed ID: 15585492
    [No Abstract]   [Full Text] [Related]  

  • 4. Radioimmunotherapy for non-Hodgkin's lymphoma.
    Friedberg JW
    Clin Cancer Res; 2004 Dec; 10(23):7789-91. PubMed ID: 15585609
    [No Abstract]   [Full Text] [Related]  

  • 5. Radiolabeled immunotherapy in non-Hodgkin's lymphoma treatment: the next step.
    Otte A; van de Wiele C; Dierckx RA
    Nucl Med Commun; 2009 Jan; 30(1):5-15. PubMed ID: 19020470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conventional treatments for non-Hodgkin's lymphoma: the need for new therapies.
    White CA; Wiseman G
    J Nucl Med; 1999 Nov; 40(11):1967-8. PubMed ID: 10565795
    [No Abstract]   [Full Text] [Related]  

  • 7. Biokinetics and dosimetry of 188Re-anti-CD20 in patients with non-Hodgkin's lymphoma: preliminary experience.
    Torres-García E; Ferro-Flores G; Arteaga de Murphy C; Correa-González L; Pichardo-Romero PA
    Arch Med Res; 2008 Jan; 39(1):100-9. PubMed ID: 18068002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pretargeted radioimmunotherapy of non-Hodgkin's lymphoma: best of both worlds?
    Boerman OC; Oyen WJ; Corstens FH
    Cancer Biother Radiopharm; 2000 Feb; 15(1):1-5. PubMed ID: 10740647
    [No Abstract]   [Full Text] [Related]  

  • 9. Radioimmunotherapy of relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
    Dillman RO
    Curr Hematol Rep; 2003 Jan; 2(1):30-7. PubMed ID: 12901152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Harnessing the energy: development of radioimmunotherapy for patients with non-Hodgkin's lymphoma.
    Gregory SA; Hohloch K; Gisselbrecht C; Tobinai K; Dreyling M
    Oncologist; 2009; 14 Suppl 2():4-16. PubMed ID: 19819920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update: NCCN non-Hodgkin's lymphoma clinical practice guidelines.
    Czuczman MS
    J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 3():S-46-52. PubMed ID: 23570100
    [No Abstract]   [Full Text] [Related]  

  • 12. Impact of nodal regression on radiation dose for lymphoma patients after radioimmunotherapy.
    Hartmann Siantar CL; DeNardo GL; DeNardo SJ
    J Nucl Med; 2003 Aug; 44(8):1322-9. PubMed ID: 12902424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New directions in radioimmunotherapy of non-Hodgkin's lymphoma.
    DeNardo GL
    Clin Lymphoma; 2004 Oct; 5 Suppl 1():S4. PubMed ID: 15498148
    [No Abstract]   [Full Text] [Related]  

  • 14. Radioimmunotherapy for lymphoma.
    Zelenetz AD
    Curr Opin Oncol; 1999 Sep; 11(5):375-80. PubMed ID: 10505774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is high-dose radioimmunotherapy needed in non-Hodgkin's lymphoma? Against.
    von Schilling C
    Eur J Nucl Med Mol Imaging; 2002 Sep; 29(9):1254-6. PubMed ID: 12418478
    [No Abstract]   [Full Text] [Related]  

  • 16. Practical and clinical benefits of radioimmunotherapy lead to advantages in cost-effectiveness in the treatment of patients with non-Hodgkin's lymphoma.
    Otte A; Thompson SL
    Nucl Med Commun; 2006 Oct; 27(10):753-6. PubMed ID: 16969255
    [No Abstract]   [Full Text] [Related]  

  • 17. Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab.
    Lindén O; Hindorf C; Cavallin-Ståhl E; Wegener WA; Goldenberg DM; Horne H; Ohlsson T; Stenberg L; Strand SE; Tennvall J
    Clin Cancer Res; 2005 Jul; 11(14):5215-22. PubMed ID: 16033839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is high-dose radioimmunotherapy needed in non-Hodgkin's lymphoma? For.
    Behr TM
    Eur J Nucl Med Mol Imaging; 2002 Sep; 29(9):1248-54. PubMed ID: 12418465
    [No Abstract]   [Full Text] [Related]  

  • 19. Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with zevalin, a 90Y-labeled anti-CD20 monoclonal antibody.
    Wiseman GA; White CA; Witzig TE; Gordon LI; Emmanouilides C; Raubitschek A; Janakiraman N; Gutheil J; Schilder RJ; Spies S; Silverman DH; Grillo-López AJ
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3281s-3286s. PubMed ID: 10541376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Commentary: let the tail wag the dog: the case for radioimmunotherapy of low-grade follicular lymphoma.
    Plastaras JP; Glatstein E; Schuster SJ
    Oncologist; 2008 Jun; 13(6):655-6. PubMed ID: 18586920
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.